PACTR202102694561794尚未招募3 期
A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 4,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Month(s) 至 23 Month(s)（—）
- 性别
- All
入选标准
- •For standard vaccination regime, the child is 5-17 months of age at the time of first vaccination.
- •For seasonal vaccination regime, the child is 5-48 months of age at the time of first vaccination.
- •Signed informed consent/thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child to join the trial.
- •The investigator believes that the parents/guardians can and will comply with the requirements of the protocol if the child is enrolled in the study.
- •The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial.
排除标准
- •The child has previously received a malaria vaccine.
- •The child is enrolled in another malaria intervention trial.
- •The child has a history of allergic disease or reactions likely to be exacerbated by any component of the malaria or control vaccine.
- •The child has a history of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunisations.
- •The child has major congenital defects.
- •The child has anaemia associated with clinical signs of symptoms of decompensation, or a haemoglobin of = 5.0 g/dL.
- •The child has had a blood transfusion within one month of enrolment.
- •The child has been administered immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- •The child has malnutrition requiring hospital admission.
- •The child has an acute or chronic, clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests.
- •Children currently meeting the WHO criteria for HIV disease of stage 3 or 4 severity. A previous history of stage 3 or 4 disease is not an exclusion. Note: There will be no routine testing for HIV. Positive diagnoses will be recorded at screening if known.
- •The child has received an investigational drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •The child is currently participating in another clinical trial if likely to affect data interpretation of this trial
- •The child has any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
研究者
相似试验
已完成
3 期
A randomized controlled multicenter phase III trial comparing cytoreductive surgery followed by intravenous chemotherapy versus intravenous chemotherapy alone for recurrent platinum-sensitive ovarian cancercancer of the ovaries1003859410029903ovarian cancerNL-OMON35952niversitair Medisch Centrum Sint Radboud230
进行中（未招募）
1 期
A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial.CTIS2023-508156-20-00Vaestra Goetalandsregionen40
已完成
不适用
A randomised study of radiotherapy and concomitant Temodal® (temozolomide) or neoadjuvant chemotherapy followed by radiotherapy and concomitant Temodal® in patients with high grade gliomaGrade III (anaplastic astrocytoma) or grade IV (glioblastoma multiforme) tumoursMalignant neoplasm of brainCancerISRCTN45209900ordic Clinical Brain Tumour Study Group (Sweden)143
已完成
3 期
A study on treatment of COVID-19 patients with study drug along with standard of careCTRI/2020/05/025369Medanta Institute of Education and Research MIER180
进行中（未招募）
1 期
This study is for research purposes only to test plitidepsin for patients requiring hospitalization due to COVID-19.moderate COVID-19 infectionMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2020-005951-19-BGPharma Mar, S.A.609